1 retinoic acid, 2 interferon alfa, 3 and antihypertensives 4 are associated with mood changes. In humans, corticosteroids are associated with mood symptoms including mania, depression, and even psychosis that have been reported in the literature since the first use of these medications approximately 60 years ago. 5, 6 Cognitive effects, particularly deficits in declarative memory, are also common during corticosteroid exposure. 5, 7, 8 Consistent with changes in declarative memory, corticosteroid excess is associated with hippocampal atrophy. 7, 9 Another brain region sensitive to the effects of corticosteroids is the amygdala. Animal studies on stress-induced release of corticosteroids have demonstrated enhanced dendritic arborization in the basolateral complex of the amygdala during stress immobilization and, in contrast, atrophy of these neurons during chronic unpredictable stress. 10 Short-term and long-term administration of exogenous corticosteroids to rats also resulted in dendritic hypertrophy in the basolateral complex of the amygdala. 11 Human studies indicate that children with classic congenital adrenal hyperplasia 12 and Cushing disease 13 present with decreased amygdala volumes compared with controls. Moreover, adults with asthma or rheumatic diseases on long-term corticosteroid therapy had 20% smaller left and 11% smaller right amygdala volumes than controls.
14 Amygdala atrophy is also found in a variety of psychiatric disorders, including posttraumatic stress disorder, 15 unmedicated depression, 16 and bipolar disorder. 17 Animal studies demonstrate that hippocampal changes caused by corticosteroids can be prevented with N-methyl-Daspartate antagonists 18 and agents, such as phenytoin, that decrease glutamate release. 19 In humans, controlled trials suggest that mood symptoms with corticosteroids may be prevented with phenytoin 20 or lithium, 21 whereas declarative memory seems to improve using the N-methyl-D-aspartate antagonist memantine 22 and the glutamate release inhibitor lamotrigine. 23 In this report, we examined mood and amygdala volume in corticosteroid-treated patients given lamotrigine or placebo for up to 24 weeks. Given our prior report of amygdala atrophy during prescription corticosteroid therapy 14 and the moodstabilizing properties of lamotrigine in bipolar disorder, 24 we hypothesized differences in mood and amygdala volume with lamotrigine as compared with placebo.
MATERIALS AND METHODS
For a randomized double-blind study, 28 patients receiving long-term oral corticosteroid therapy were recruited from University of Texas Southwestern Medical Center clinics from August 2002 to March 2005 by trained research assistants. Upon signing an institutional review boardYapproved consent form, participants were assessed for mood with the Hamilton Depression Rating Scale (HAM-D) and Young Mania Rating Scale (YMRS) at baseline and every 2 weeks thereafter at the University of Texas Southwestern Psychoneuroendocrine Research Program clinic for up to 24 weeks. Brain magnetic resonance imaging (MRI) on a 1.5-Tesla scanner was obtained at baseline and week 24. Participants aged 18 to 65 years receiving at least 7.5 mg of prednisone for at least 6 months with no mental illnesses other than those induced by corticosteroids were included in the study. Assessments and exclusionary criteria are further elaborated in our previous article examining the effects of lamotrigine on memory and hippocampal volume. 23 The study was registered at ClinicalTrials.gov (NCT00223262).
A staff member without patient contact randomly allocated participants to a treatment group using randomizer.org and assigned numbered containers to a blinded staff member who administered the medication. Lamotrigine or identical placebo was titrated to 400 mg/d for 10 weeks unless adverse effects required a slower titration or dose reduction. Treatment group assignment remained anonymous to the researchers until all data collections were complete.
Two reliable blinded raters (S.D., S.K.) conducted anatomical measurements using BRAINS2 software 25 under the supervision of Dr Shad. Amygdala volumes were manually traced using methods delineated by Keshavan et al. 26 Raters had an intraclass correlation of 0.96 for the right amygdala and 0.95 for the left amygdala, as measured on 10 scans. All measurements were adjusted for total brain volume (TBV), which was measured in our previous study on hippocampal volume changes by raters who had an intraclass correlation of 0.95, as measured on 10 scans. 23 The amygdala is depicted in Figure 1 and defined as follows. The anterior tracings began where temporal and frontal lobes fused and the temporal stem became visible. The anteriormost point of the mamillary body demarcated the amygdala from the hippocampus posteriorly. Alveus of the hippocampus formed the inferior boundary, whereas the temporal stem created the lateral and superior boundaries. 26 The cisternal cerebral fluid formed the amygdala's medial boundary. 17 To test the effects of lamotrigine on amygdala volume (primary aim), a univariate analysis of covariance (ANCOVA) was performed for exit (week 24) amygdala volume/TBV with covariates of baseline amygdala volume/TBV, corticosteroid dose and duration, and fixed factors of gender and treatment group. Covariates and fixed factors were selected that showed significant between-group differences at baseline, correlated with the outcome measure, or that, based on prior research, could have an impact on the outcome. Analogous ANCOVA were conducted for assessing mood (secondary aim) with exit HAM-D and YMRS scores, using baseline mood scores and corticosteroid dose and duration as covariates and gender and treatment group as fixed factors. Baseline amygdala/TBV was correlated with baseline mood scores, TBV, current prednisone dose, and duration of corticosteroid therapy using Pearson correlation coefficient. Sample size was based on our previous lamotrigine study that studied cognitive changes using Rey Auditory Visual Learning Test scores. 23 
RESULTS
The 28 participants were randomized (n = 16, lamotrigine; n = 12, placebo), with 27 patients (n = 15, lamotrigine; n = 12, placebo) returning for at least 1 postbaseline assessment (intentto-treat sample) and 22 (n = 14, lamotrigine; n = 8, placebo) completing the baseline MRI. Eighteen participants (n = 8, lamotrigine; n = 10, placebo) completed the mood assessments through week 24, and 14 participants (n = 7, lamotrigine; n = 7, placebo) attended both baseline and week 24 MRI scans. Concomitant medications and reasons for study discontinuation, including adverse events, of subjects are discussed in our previous article. 23 Baseline characteristics except prednisone dose did not significantly differ between lamotrigine and placebo groups in the intent-to-treat sample ( Table 1) .
The left exit amygdala/TBV ANCOVA revealed significant effects of treatment group (F 1,14 = 6.036, P = 0.044), whereas for the right exit amygdala volume, treatment group (F 1,14 = 2.676, P = 0.146) did not attain significance (Table 2) . Neither exit (F 1,27 = 0.804, P = 0.381) nor week 24 (F 1,18 = 1.939, P = 0.191) HAM-D ANCOVA showed a significant treatment group effect (Table 2) . Similarly, between-group differences did not reach significance in either exit (F 1,27 = 0.573, P = 0.458) or week 24 (F 1,18 = 2.674, P = 0.130) YMRS ANCOVA ( Table 2) .
Trends toward significant negative baseline correlations were observed between current prednisone dose and left baseline amygdala volume (r = j0.381, P = 0.081) and between baseline YMRS scores and right baseline amygdala volume (r = j0.364, P = 0.096).
DISCUSSION
We previously reported reduction in both the hippocampus 7 and amygdala 14 in corticosteroid-treated patients. Animal literature, however, suggests that glutamate release inhibitors prevent the effects of corticosteroid on the hippocampus. 18, 19 In humans, the glutamate release inhibitor lamotrigine improved declarative memory but did not ameliorate the atrophic effects of corticosteroids on the hippocampus. 23 To our knowledge, the impact of glutamate release inhibitors on the amygdala had not been explored until the current study.
The principal finding of this study is that lamotrigine attenuated the reduction of amygdala volume in corticosteroidtreated patients. Thus, lamotrigine may be associated with improvements in memory and morphological brain changes in corticosteroid-treated patients.
We found a negative trend between baseline left amygdala volume and current prednisone dose, corresponding with our prior report that found an inverse relationship between hippocampal volume and prednisone dose in these same patients. 7 However, in another report, we observed a negative correlation between amygdala volume and prednisone duration but not dose.
14 Thus, the interaction between prednisone exposure and amygdala volume seems complex. We found another negative trend between baseline YMRS score and right baseline amygdala volume, implying that right amygdala volume may be inversely associated with severity of manic symptoms in corticosteroidtreated patients.
When assessing the findings of this study, several limitations must be considered. First, our sample size was modest, and larger trials are warranted to confirm these preliminary observations. Second, our sample population was complex; the patients had serious medical illnesses and were on multiple concomitant medications. This complication, however, is inherent to research in corticosteroid-treated patients. Third, the assessment period of 24 weeks was relatively brief. With longer lamotrigine treatment, greater changes in amygdala volume and, perhaps, HAM-D and YMRS scores might have been observed. Fourth, our findings from corticosteroid-treated patients may or may not be generalizable to amygdala atrophy in other excess corticosteroid conditions, such as classic congenital adrenal hyperplasia, 12 Cushing syndrome, 13 unmedicated depression, 16 or bipolar disorder. 17 Fifth, the relatively low baseline levels of mania and depression in our sample limited our ability to detect changes in these mood symptoms. Sixth, given the exploratory nature of the data analysis, corrections for multiple comparisons were not performed, potentially increasing the possibility of type I error.
In summary, this study suggests that lamotrigine may attenuate amygdala volume atrophy in patients on long-term treatment with corticosteroids. Research with animal models is needed to explain the mechanism by which lamotrigine buffers the atrophic effect of corticosteroids on the amygdala, although reduction in glutamate is a possible explanation. Further investigations with larger sample sizes of corticosteroid-treated patients and longer assessment periods are required to establish whether continuous lamotrigine treatment persistently improves amygdala volume and mood. 
AUTHOR DISCLOSURE INFORMATION

